Selected article for: "available information and China province"
Author: Huang, Rui; Zhu, Li; Xue, Leyang; Yan, Xuebing; Wang, Jian; Huang, Songping; Zhang, Biao; Xu, Tianmin; Ji, Fang; Li, Chunyang; Ming, Fang; Zhao, Yun; Li, Yang; Cheng, Juan; Wang, Yinling; Shao, Huaping; Hong, Shuqin; Chen, Kang; Zhao, Xiang-an; Sang, Dawen; Zou, Lei; Zhao, Haiyan; Guan, Xinying; Chen, Xiaobing; Xu, Biyun; Xia, Juan; Chen, Yuxin; Yan, Xiaomin; Wei, Jie; Liu, Jiacheng; Liu, Longgen; Zhu, Chuanwu; Wu, Chao
Title: Clinical and virological course of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center cohort study
  • Cord-id: d46p97k9
  • Document date: 2021_7_14
    • ID: d46p97k9
    Snippet: BACKGROUND: The clinical and virological course of patients with coronavirus disease 2019 (COVID-19) are lacking. We aimed to describe the clinical and virological characteristics of COVID-19 patients from 10 designated hospitals in 10 cities of Jiangsu province, China. The factors associated with the clearance of SARS-CoV-2 were investigated. METHODS: A total of 328 hospitalized patients with COVID-19 were retrospectively recruited. The epidemiological, clinical, laboratory, radiology and treat
    Document: BACKGROUND: The clinical and virological course of patients with coronavirus disease 2019 (COVID-19) are lacking. We aimed to describe the clinical and virological characteristics of COVID-19 patients from 10 designated hospitals in 10 cities of Jiangsu province, China. The factors associated with the clearance of SARS-CoV-2 were investigated. METHODS: A total of 328 hospitalized patients with COVID-19 were retrospectively recruited. The epidemiological, clinical, laboratory, radiology and treatment data were collected. The associated factors of SARS-CoV-2 clearance were analyzed. RESULTS: The median duration of hospitalization was 16.0 days (interquartile range [IQR] 13.0–21.0 days). On multivariate Cox regression analysis, age > 60 years (hazard ratio [HR] 0.643, 95% confidence interval [CI] 0.454–0.911, P = 0.013) was associated with the delayed SARS-CoV-2 clearance, while the atomized inhalation of interferon α-2b could improve the clearance of SARS-CoV-2 (HR, 1.357, 95% CI 1.050–1.755, P = 0.020). Twenty-six (7.9%) patients developed respiratory failure and 4 (1.2%) patients developed ARDS. Twenty (6.1%) patients were admitted to the ICU, while no patient was deceased. CONCLUSIONS: Our study found that age > 60 years was associated with the delayed SARS-CoV-2 clearance, while treated with atomized inhalation of interferon α-2b could promote the clearance of SARS-CoV-2. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-021-01615-y.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and additional file: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and admission lymphopenia: 1, 2
    • acute ards respiratory distress syndrome and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lopinavir ritonavir group: 1
    • acute ards respiratory distress syndrome and lopinavir ritonavir treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • additional file and admission time: 1, 2, 3, 4, 5, 6, 7
    • additional file and local center: 1
    • additional file and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • additional file and lopinavir ritonavir group: 1, 2, 3, 4, 5, 6
    • additional file and lopinavir ritonavir treatment: 1, 2
    • admission lymphopenia and lopinavir ritonavir: 1
    • admission time and local center: 1, 2, 3
    • admission time and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission time and lopinavir ritonavir group: 1, 2, 3, 4
    • admission time and lopinavir ritonavir treatment: 1, 2, 3, 4, 5, 6
    • admission time and lymphocyte normal range: 1
    • local center and lopinavir ritonavir: 1, 2